Microsatellite instability derived JAK1 frameshift mutations are associated with tumor immune evasion in endometrioid endometrial cancer

Oncotarget

Volumn 7, Issue 26, 2016, Pages 39885-39893

  Stelloo, Ellen ^a   Versluis, Marco A ^b   Nijman, Hans W ^b   De Bruyn, Marco ^b   Plat, Annechien ^b   Osse, Elisabeth M ^a   Van Dijk, Reinhardt H ^a   Nout, Remi A ^a   Creutzberg, Carien L ^a   De Bock, Geertruida H ^b   Smit, Vincent T ^a   Bosse, Tjalling ^a   Hollema, Harry ^b  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

Antigen presentation machinery; Endometrial cancer; HLA class I; JAK1; Microsatellite instability

Indexed keywords

HLA ANTIGEN CLASS 1; JANUS KINASE 1; LMP7 PROTEIN; MEMBRANE PROTEIN; TRANSPORTER ASSOCIATED WITH ANTIGEN PROCESSING 1; UNCLASSIFIED DRUG; DNA; JAK1 PROTEIN, HUMAN; MICROSATELLITE DNA; PROTEASOME;

ARTICLE; CANCER PROGNOSIS; CANCER SURVIVAL; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; ENDOMETRIUM CANCER; FEMALE; FRAMESHIFT MUTATION; GENE FREQUENCY; GENETIC ASSOCIATION; HUMAN; HUMAN TISSUE; IMMUNE EVASION; IMMUNOPATHOGENESIS; JAK1 GENE; MAJOR CLINICAL STUDY; MICROSATELLITE INSTABILITY; PROTEIN EXPRESSION; TUMOR ESCAPE; WILD TYPE; AGED; ANTIGEN PRESENTATION; COHORT ANALYSIS; DNA METHYLATION; DNA MUTATIONAL ANALYSIS; ENDOMETRIUM TUMOR; GENETICS; METABOLISM; MIDDLE AGED; PROGNOSIS; SEQUENCE ANALYSIS; TUMOR RECURRENCE;

AGED; ANTIGEN PRESENTATION; COHORT STUDIES; DNA METHYLATION; DNA MUTATIONAL ANALYSIS; DNA, NEOPLASM; ENDOMETRIAL NEOPLASMS; FEMALE; FRAMESHIFT MUTATION; HISTOCOMPATIBILITY ANTIGENS CLASS I; HUMANS; JANUS KINASE 1; MICROSATELLITE INSTABILITY; MICROSATELLITE REPEATS; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; PROTEASOME ENDOPEPTIDASE COMPLEX; SEQUENCE ANALYSIS, RNA;

EID: 84983002234     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.9414     Document Type: Article

References (28)

1. Kandoth C, Schultz N, Cherniack AD, Akbani R, Liu Y, Shen H, Robertson AG, Pashtan I, Shen R, Benz CC, Yau C, Laird PW, Ding L, et al. Integrated genomic characterization of endometrial carcinoma. Nature. 2013; 497:67-73.
2. Imai K and Yamamoto H. Carcinogenesis and microsatellite instability: the interrelationship between genetics and epigenetics. Carcinogenesis. 2008; 29:673-80.
3. Duval A, Reperant M, Compoint A, Seruca R, Ranzani GN, Iacopetta B and Hamelin R. Target gene mutation profile differs between gastrointestinal and endometrial tumors with mismatch repair deficiency. Cancer Res. 2002; 62:1609-12.
4. Kim TM, Laird PW and Park PJ. The landscape of microsatellite instability in colorectal and endometrial cancer genomes. Cell. 2013; 155:858-68.
5. Ferreira AM, Tuominen I, Sousa S, Gerbens F, van DijkBos K, Osinga J, Kooi KA, Sanjabi B, Esendam C, Oliveira C, Terpstra P, Hardonk M, van der Sluis T, et al. New target genes in endometrial tumors show a role for the estrogen-receptor pathway in microsatellite-unstable cancers. Hum Mutat. 2014; 35:1514-23.
6. Myeroff LL, Parsons R, Kim SJ, Hedrick L, Cho KR, Orth K, Mathis M, Kinzler KW, Lutterbaugh J and Park K. A transforming growth factor beta receptor type II gene mutation common in colon and gastric but rare in endometrial cancers with microsatellite instability. Cancer Res. 1995; 55:5545-47.
7. Thomas SJ, Snowden JA, Zeidler MP and Danson SJ. The role of JAK/STAT signalling in the pathogenesis, prognosis and treatment of solid tumours. Br J Cancer. 2015; 113:365-71.
8. Aaronson DS and Horvath CM. A road map for those who don't know JAK-STAT. Science. 2002; 296: 1653-55.
9. Murray PJ. The JAK-STAT signaling pathway: input and output integration. J Immunol. 2007; 178:2623-29.
10. Ren Y, Zhang Y, Liu RZ, Fenstermacher DA, Wright KL, Teer JK and Wu J. JAK1 truncating mutations in gynecologic cancer define new role of cancer-associated protein tyrosine kinase aberrations. Sci Rep. 2013; 3: 3042.
11. Vesely MD, Kershaw MH, Schreiber RD and Smyth MJ. Natural innate and adaptive immunity to cancer. Annu Rev Immunol. 2011; 29: 235-71.
12. Schreiber RD, Old LJ and Smyth MJ. Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion. Science. 2011; 331:1565-70.
13. Bijen CB, Bantema-Joppe EJ, de Jong RA, Leffers N, Mourits MJ, Eggink HF, van der Zee AG, Hollema H, de Bock GH and Nijman HW. The prognostic role of classical and nonclassical MHC class I expression in endometrial cancer. Int J Cancer. 2010; 126:1417-27.
14. de Jong RA, Boerma A, Boezen HM, Mourits MJ, Hollema H and Nijman HW. Loss of HLA class I and mismatch repair protein expression in sporadic endometrioid endometrial carcinomas. Int J Cancer. 2012; 131:1828-36.
15. Yakabe K, Murakami A, Nishimoto Y, Kajimura T, Sueoka K and Sugino N. Clinical implications of human leukocyte antigen class I expression in endometrial cancer. Mol Clin Oncol. 2015; 3:1285-90.
16. van Gool IC, Eggink FA, Freeman-Mills L, Stelloo E, Marchi E, de Bruyn M, Palles C, Nout RA, de Kroon CD, Osse EM, Klenerman P, Creutzberg CL, Tomlinson IP, et al. POLE Proofreading Mutations Elicit an Antitumor Immune Response in Endometrial Cancer. Clin Cancer Res. 2015; 21:3347-55.
17. Le DT, Uram JN, Wang H, Bartlett BR, Kemberling H, Eyring AD, Skora AD Luber BS, Azad NS, Laheru D, Biedrzycki B, Donehower TC, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015; 372:2509-20.
18. Shin D, Garcia-Diaz A, Zaretsky J, Escuin-Ordinas H, Hu-Lieskovan S, Berent-Maoz B, Comin-Anduix B and Ribas A. Innate resistance of PD-1 blockade through loss of function mutations in JAK resulting in inability to express PD-L1 upon interferon exposure. J Immunother Cancer. 2015; 3: P311.
19. Creutzberg CL, van Putten WL, Koper PC, Lybeert ML, Jobsen JJ, Warlam-Rodenhuis CC, De Winter KA, Lutgens LC, van den Bergh AC, Steen-basanik E, Beerman H and van Lent M. Surgery and postoperative radiotherapy versus surgery alone for patients with stage-1 endometrial carcinoma: multicentre randomised trial. PORTEC Study Group. Post Operative Radiation Therapy in Endometrial Carcinoma. Lancet. 2000; 355:1404-11.
20. Nout RA, Smit VT, Putter H, Jurgenliemk-Schulz IM, Jobsen JJ, Lutgens LC, van der Steen-Banasik EM, Mens JW, Slot A, Kroese MC, van Bunningen BN, Ansink AC, van Putten WL, et al. Vaginal brachytherapy versus pelvic external beam radiotherapy for patients with endometrial cancer of high-intermediate risk (PORTEC-2): an open-label, non-inferiority, randomised trial. Lancet. 2010; 375:816-23.
21. Cabrera CM, Jimenez P, Cabrera T, Esparza C, Ruiz Cabello F and Garrido F. Total loss of MHC class I in colorectal tumors can be explained by two molecular pathways: beta2-microglobulin inactivation in MSI-positive tumors and LMP7/TAP2 downregulation in MSI-negative tumors. Tissue Antigens. 2003; 61:211-19.
22. Kang JK, Yoon SJ, Kim NK and Heo DS. The expression of MHC class I, TAP1/2, and LMP2/7 gene in human gastric cancer cell lines. Int J Oncol. 2000;16:1159-63.
23. Corthay A, Skovseth DK, Lundin KU, Rosjo E, Omholt H, Hofgaard PO, Haraldsen G and Bogen B. Primary antitumor immune response mediated by CD4+ T cells. Immunity. 2005; 22:371-83.
24. Kloor M, Michel S and von Knebel DM. Immune evasion of microsatellite unstable colorectal cancers. Int J Cancer. 2010; 127:1001-10.
25. Xiong H, Zhang ZG, Tian XQ, Sun DF, Liang QC, Zhang YJ, Lu R, Chen YX and Fang JY. Inhibition of JAK1, 2/STAT3 signaling induces apoptosis, cell cycle arrest, and reduces tumor cell invasion in colorectal cancer cells. Neoplasia. 2008; 10:287-97.
26. Stelloo E, Nout RA, Osse EM, Jurgenliemk-Schulz IJ, Jobsen JJ, Lutgens LC, van der Steen-Basanik EM, Nijman HW, Putter H, Bosse T, Creutzberg CL, Smit VT. Improved risk assessment by integrating molecular and clinicopathological factors in early-stage endometrial cancer - combined analysis of PORTEC cohorts. Clin cancer res. 2016.
27. Stelloo E, Bosse T, Nout RA, MacKay HJ, Church DN, Nijman HW, Leary A, Edmondson RJ, Powell ME, Crosbie EJ, Kitchener HC, Mileshkin L, Pollock PM, et al. Refining prognosis and identifying targetable pathways for high-risk endometrial cancer; a TransPORTEC initiative. Mod Pathol. 2015; 28:836-44.
28. Ruiter DJ, Ferrier CM, van Muijen GN, Henzen-Logmans SC, Kennedy S, Kramer MD, Nielsen BS and Schmitt M. Quality control of immunohistochemical evaluation of tumour-associated plasminogen activators and related components. European BIOMED-1 Concerted Action on Clinical Relevance of Proteases in Tumour Invasion and Metastasis. Eur J Cancer. 1998; 34:1334-40.